Positive results for Cosentyx in hidradenitis suppurativa

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis, said Swiss pharma giant Novartis (NOVN: VX), which today announced that the prestigious medical journal The Lancet has published long-term data from the pivotal SUNSHINE and SUNRISE trials evaluating Cosentyx in moderate-to-severe HS.

In the Phase III trials, Cosentyx treatment response rates continued to improve beyond the primary endpoint analysis at Week 16 to more than 55% of patients achieving a HS Clinical Response (HiSCR) measure at Week 52.

Overall, at Week 52, more than 60% of patients were free of flares. Additionally, more than 50% experienced a meaningful reduction in pain, which has been identified by patients as the most burdensome symptom of HS.